Fresenius Medical Care AG
FMSDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 8, 2026 | $0.86 | 2026-05-22 | 2026-05-22 |
| June 6, 2025 | $0.81 | 2025-05-23 | 2025-05-23 |
| June 3, 2024 | $0.64 | 2024-05-17 | 2024-05-20 |
| June 1, 2023 | $0.60 | 2023-05-17 | 2023-05-18 |
| May 27, 2022 | $0.71 | 2022-05-13 | 2022-05-16 |
Dividends Summary
- Consistent Payer: Fresenius Medical Care AG has rewarded shareholders with 24 dividend payments over the past 23 years.
- Total Returned Value: Investors who held FMS shares during this period received a total of $15.45 per share in dividend income.
- Latest Payout: The most recent dividend of $0.86/share was paid 40 days ago, on June 8, 2026.
- Yield & Schedule: FMS currently pays dividends yearly with an annual yield of 3.59%.
- Dividend Growth: Since 2003, the dividend payout has grown by 136.0%, from $0.37 to $0.86.
Company News
The U.S. arteriovenous fistula devices market is projected to grow from $112 million in 2025 to $120 million by 2033, driven by rising end-stage renal disease cases and increasing demand for advanced vascular access solutions.
Quest Diagnostics reported strong Q1 2025 results, with revenue and earnings beating estimates. The company reaffirmed its full-year guidance and announced strategic acquisitions and partnerships, fueling confidence in its outlook.
The global wearable artificial organs market is expected to grow significantly from $11.17 billion in 2024 to $64.19 billion by 2035, driven by government initiatives, technological advancements, and patient preference for non-invasive solutions. North America and Asia Pacific are expected to be the key growth regions.
The report provides a comprehensive analysis of the China infusion systems market, including infusion pumps and infusion pump disposables, with data from 2018 to 2033. It covers key market information, company profiles, pipeline products, and recent developments.
The U.S. compounding pharmacies market is expected to grow at a CAGR of 4.06% from 2023 to 2029, driven by the growing demand for compounded bioidentical menopausal hormone therapy among women and the increasing adoption of advanced technologies in the industry.
